Details

Autor(en) / Beteiligte

• Aparicio Serrano, Ana
• Gallego Jiménez, Elma
• Castro Rodríguez, Javier
• Soto Escribano, Pilar
• Iglesias Flores, Eva
• Marín Pedrosa, Sandra
• Benítez, José Manuel

Titel

Mesalazine induced interstitial pneumonitis in the COVID era

Ist Teil von

• Revista española de enfermedades digestivas, 2022-07, Vol.114 (7), p.429-430

Ort / Verlag

Spain: Sociedad Espanola de Patologia Digestivas

Erscheinungsjahr

2022

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Mesalazine is the most widely used aminosalicylate for induction and maintenance of remission in patients with mild-to-moderate ulcerative colitis (UC). Drug-induced hypersensitivity pneumonitis is considered very rare (<1/10.000 patients). Due to its rarity and the scarce cases reported, mesalazine-induced lung injury needs to be highly suspected in a patient with onset of respiratory symptoms and UC under treatment with salicylates. It should make the clinician formulate a differential diagnosis that includes not only infections (tuberculosis, bacterial...) or the inflammatory bowel disease itself, but also the current coronavirus disease 2019 (COVID-19) since their clinical and radiological manifestations may be very similar.